SEOM clinical guidelines for cervical cancer (2019)

• DOI: 10.1007/s12094-019-02271-z
• Publication Date: 2020-01-24T14:02:57Z
• Authors: A. de Juan; A. Redondo; M. J. Rubio; Y. García; J. Cueva; L. Gaba; A. Yubero; J. Alarcón; C. Maximiano; A. Oaknin
• Keywords: Concomitant

Cervical cancer (CC) is the fourth most common in women worldwide, strongly linked to high-risk human papilloma virus infection. In high-income countries, screening programs have dramatically decreased incidence of CC; however, lack accessibility them developing countries makes CC an important cause mortality. Clinical stage relevant prognostic factor CC. The new FIGO staging system published 2018 more accurate than previous one since it takes into account lymph node status. early stages, primary treatment surgery-with some concerns recently raised regarding minimally invasive surgery because might decrease survival-or radiotherapy, whereas concomitant chemo-radiotherapy conventional approach locally advanced stages. For recurrent or metastatic CC, combination chemotherapy plus bevacizumab preferred therapy. Immunotherapy based on checkpoint inhibitors evolving as election therapy following failure platinum